Biochimica et Biophysica Acta (BBA) - General Subjects
Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence
Introduction
The essential role of mitochondria in cellular bioenergetics and survival has been well established [1], [2], [3]. Further, mitochondrial dysfunction has been suggested to play a pivotal role in neurodegenerative disorders, including Alzheimer's disease (AD) [1], [4], [5]. It has been shown that brain metabolism is declined in AD patients at least a decade before disease diagnosis [1], [6], [7], [8], [9]. Dysfunction in glucose metabolism, bioenergetics and mitochondrial function are consistent antecedents to development of Alzheimer pathology [10], [11], [12], [13], [14], [15], [16], [17], [18]. Recently we demonstrated that mitochondrial bioenergetic deficits precede Alzheimer's pathology in the female triple transgenic mouse model of Alzheimer's disease (3xTgAD) [7]. These antecedent declines in brain metabolism indicate a potential causal role of mitochondrial bioenergetics in AD pathogenesis and disease progression.
Basic science analyses indicate that the endogenous estrogen, 17β-estradiol (E2), significantly increased glucose uptake, glucose metabolism, insulin growth factor signaling and the energetic capacity of brain mitochondria by maximizing aerobic glycolysis (oxidative phosphorylation coupled to pyruvate metabolism) [1], [6], [19]. The enhanced aerobic glycolysis in the aging brain would be predicted to prevent conversion of the brain to using alternative sources of fuel such as the ketone body pathway characteristic of AD [1], [6]. The ability of estrogen to sustain glucose as the primary fuel source in brain by enhancing glucose transport, uptake and aerobic glycolysis (oxidative phosphorylation coupled to pyruvate metabolism) is likely linked to its ability to prevent age-associated metabolic decline in brain and thus could be a key mechanism whereby estrogen reduces the risk of AD in postmenopausal women [1], [6], [19], [20], [21], [22], [23], [24].
Reproductive senescence is a multifactorial process with a high degree of interpersonal variability and subject to a host of beneficial or detrimental influences. As such, reproductive senescence is an illustrative example of both the aging process and of modifiers of aging, such as ovarian hormone status, which both contribute to alteration in brain metabolic profile. In the current study, we sought to determine the impact of loss of ovarian hormones associated with reproductive senescence on mitochondrial function, particularly mitochondrial bioenergetics. We further investigate the individual variability in metabolic profile during the reproductive senescence transition. The results presented demonstrate that loss of ovarian hormones during reproductive senescence parallels the accelerated decline in mitochondrial bioenergetics, linking the loss of ovarian hormones to the development of a hypometabolic brain phenotype which could be clinically relevant to the in prodromal phase of AD. Collectively current clinical findings and findings from this study provide a plausible mechanism of increased AD risk in menopausal women.
Section snippets
Transgenic mice
Colonies of 3xTgAD and nonTg mouse strain (C57BL6/129S;Gift from Dr. Frank Laferla, University of California, Irvine)[25] were bred and maintained at the University of Southern California (Los Angeles, CA) following National Institutes of Health guidelines on use of laboratory animals and an approved protocol by the University of Southern California Institutional Animal Care and Use Committee. Mice were housed on 12-h light/dark cycles and provided ad libitum access to food and water. Only
Results
In the process of conducting an analysis of bioenergetic changes in aging to determine if changes in mitochondrial preceded development of AD pathology, we observed that a decline in bioenergetics occurred after the development of AD pathology but which corresponded to the transition of reproductive senescence. Data presented in Fig. 1, Fig. 2, Fig. 4, Fig. 5 are derived from the quantitative data presented in Fig. 4 and Table 1 of the PNAS manuscript [7]. In the previous publication the
Discussion
Increasing evidence links mitochondrial dysfunction in multiple neurodegenerative disorders, such as Alzheimer's disease (AD) [11]. We previously demonstrated that mitochondrial bioenergetic deficits precede AD pathology in the female triple transgenic AD mouse model [7], suggesting a potential causal role of mitochondrial bioenergetic deficiency in AD pathogenesis. Clinically, Alzheimer's pathology is accompanied by a decrease in expression and activity of enzymes involved in mitochondrial
Acknowledgments
This study was supported by National Institute on Aging Grant 2R01AG032236 (to RDB; Project 1 EC), National Institute on Aging Grant 5P01AG026572 (to RDB) and the Kenneth T. and Eileen L. Norris Foundation (R.D.B.). We gratefully thank Dr. Ronald W. Irwin for contributions to mitochondrial isolation and Dr. Frank M Laferla for providing the triple-transgenic Alzheimer's disease mouse model.
References (35)
The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications
Trends Neurosci.
(2008)Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease
Adv. Drug Deliv. Rev.
(2008)- et al.
Insights into amyloid-beta-induced mitochondrial dysfunction in Alzheimer disease
Free Radic. Biol. Med.
(2007) - et al.
Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes
J. Neurol. Sci.
(2007) RD Menopause and Mitochondria: Windows into Estrogen Effects on Alzheimer's Disease Risk and Therapy: Progress in Brain Research
Neuroendocrinology
(2010)- et al.
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction
Neuron
(2003) - et al.
Ketone body synthesis in the brain: possible neuroprotective effects
Prostaglandins Leukot. Essent. Fatty Acids
(2004) - et al.
Rat brain glycolysis regulation by estradiol-17 beta
Biochim. Biophys. Acta
(1992) Neuron–glia metabolic coupling and plasticity
J. Exp. Biol.
(2006)A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine
Annu. Rev. Genet.
(2005)
The neurodegenerative mitochondriopathies
J. Alzheimers Dis.
Pathways towards and away from Alzheimer's disease
Nature
Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease
Proc. Natl Acad. Sci. U. S. A.
Hypometabolism as a therapeutic target in Alzheimer's disease
BMC Neurosci.
Gene microarrays in hippocampal aging: statistical profiling identifies novel processes correlated with cognitive impairment
J. Neurosci.
Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses
Proc. Natl Acad. Sci. U. S. A.
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia
Proc. Natl. Acad. Sci. U. S. A.
Cited by (123)
Altered glucose metabolism in Alzheimer's disease: Role of mitochondrial dysfunction and oxidative stress
2022, Free Radical Biology and MedicineCitation Excerpt :However, during cognition disorders, hypometabolism of glucose and Aβ are regulated independently from each other [351]. Moreover, elevated production of ketone bodies has been observed during AD [371]. Hypometabolism of glucose during AD enforces metabolic shift in the brain from glucose to lipid for survival, which again correlates with amyloid and TAU pathology [372].
Sex differences in Alzheimer's disease: metabolic reprogramming and therapeutic intervention
2021, Trends in Endocrinology and MetabolismReactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer's disease
2021, Ageing Research Reviews